WALTHAM, Mass. - Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage biotechnology firm focused on muscle disease treatments, announced today the appointment of John Cox as its new president, chief executive officer (CEO), and Board of Directors member.
Cox, an industry veteran with a track record in rare disease commercialization, takes over from Joshua Brumm, who is stepping down to transition into healthcare investing. Brumm will remain as an advisor to ensure a smooth handover.
Cox brings a wealth of experience to Dyne, having previously led Bioverativ Inc., a Biogen Inc (NASDAQ:BIIB). spin-off, before its acquisition by Sanofi (EPA:SASY) (NASDAQ:SNY) S.A. He also served as CEO of Repertoire Immune Medicines and held various senior roles at Biogen over a 14-year span. Cox's academic credentials include an MBA from the University of Michigan and a background in cell biology and biology from California State University and Arizona State University, respectively.
His appointment comes at a pivotal moment for Dyne, as the company is advancing its clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), as well as a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). Using its proprietary FORCE™ platform, Dyne aims to develop oligonucleotide therapeutics designed to enhance delivery to muscle tissue.
The outgoing CEO, Brumm, expressed pride in Dyne's achievements under his leadership since 2019, particularly in transitioning from a research organization to a clinical-stage company. Jason Rhodes, chairman of Dyne's Board of Directors, commended Brumm's contributions and welcomed Cox, citing his deep executive experience and expertise in global operations.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.